Strand Life Sciences

We Solve Problems in Genomics

[Indian Pharma Post @indpharmapost]

Announcing distinguished speakers for upcoming discussion by #IndianPharmaPost:

🎙️Dr. Ramesh Hariharan, CEO,@StrandLife
🎙️Dr. Debojyoti Dhar, Director, @LeucineRichBio
🎙️Kapil Ravi, Director, ComputeGenomics
🎙️Hitesh Goswami, CEO, @4baseCare

Register: https://t.co/QVu1wDPrgL

[Strand Life Sciences @StrandLife]

https://t.co/HlWYUKnYZR

[Strand Life Sciences @StrandLife]

We are thrilled to attend the Animal AgTech Innovation Summit on April 8th and 9th in Fort Worth, Texas where leaders from across livestock production, animal health, and agricultural technology will gather to examine the next phase of innovation that impacts animal agriculture.

With the adoption of data-driven systems, advanced genetics, and AI-enabled monitoring across animal agriculture, the need for robust computational methods and reliable biological insight becomes increasingly important. At Strand, we're poised to bring our expertise in therapeutics and health care towards advancing animal health initiatives. We look forward to discussions on how quantitative modeling, bioinformatics, and engineering approaches can support resilient and efficient livestock systems.

If you plan to attend the summit, we welcome the opportunity to connect and exchange perspectives.
Krishna Sridharan, Ph.D.
Ernie Hobbs

hashtag#AnimalAgTech hashtag#AnimalAgriculture hashtag#LivestockInnovation hashtag#AnimalHealth hashtag#AgriTech hashtag#AgInnovation

[Strand Life Sciences @StrandLife]

Strand is excited to participate in the 44th Annual J.P. Morgan Healthcare Conference, January 12-15, in San Francisco.

Our CEO, Dr. Ramesh Hariharan, along with the team, Radhakrishna Bettadapura, Jaya Singh, PhD and Ernie Hobbs, will be at the event. Feel free to reach out to schedule a meeting.

We look forward to connecting with you!

hashtag#JPM26 hashtag#JPM2026

[ETHealthWorld @ETHealthWorld]

RIL Plans Foray Into Genomic Diagnostics

#Genomics I #Diagnostics I #Public_health I #Preventive_care I @StrandLife I @reliancegroup

Read more:
https://t.co/BD3EtEOc8u

[Sid Shah @Sid_Healthcare]

#India Mukesh Ambani to shake up #healthcare #diagnostics as Reliance plans to offer #genomictesting under ₹1,000, down from current rates of ₹10,000, leveraging @StrandLife https://t.co/FecdE8CWHR

[Strand Life Sciences @StrandLife]

We had a great time presenting at Seqera Sessions in Durham last week! It was a privilege to share how Strand Life Sciences is using Nextflow and the Seqera Platform to drive massive efficiency gains for our clients.

If you are interested in how we achieved a 35x increase in throughput and a 66% reduction in costs, check out the full case study below. Thanks to the Seqera team for hosting such a fantastic event!

hashtag#Nextflow hashtag#Seqera hashtag#Bioinformatics hashtag#Genomics hashtag#PipelineDevelopment hashtag#LifeSciences hashtag#CloudComputing

[Seqera @SeqeraLabs]

After a fantastic morning of @nextflowio training, the team are ready for an afternoon of #Seqera Sessions here in Durham, North Carolina! 🇺🇸 Get ready for an afternoon of live demos and expert talks, including from @StrandLife

[Seqera @SeqeraLabs]

⌛ Last chance! Seqera Sessions Durham is happening tomorrow! 🇺🇸 Join us in the heart of North Carolina’s Research Triangle for a day of @nextflowio training, expert talks, and networking with the local bioinformatics community!

🎟️ Register now: https://t.co/FPBLfDF23U

[Seqera @SeqeraLabs]

New Case Study with @StrandLife 🎉

Strand faced growing demands across pharma, diagnostics, and precision medicine clients. The bottleneck: their existing workflow management system.

To address this, they undertook a strategic initiative to standardize their bioinformatics operations. By migrating legacy pipelines to @nextflowio and deploying on Seqera, Strand:

☑��� Reduced workflow execution time by up to 55%
☑️ Scaled sample throughput by 35x
☑️ Achieved ~66% reduction in total costs

📚 Read now: https://t.co/xPwUnCp1BP

[Strand Life Sciences @StrandLife]

Excited to see @Alnylam join the Alliance for Genomic Discovery, expanding diverse clinical genomic data to fuel precision medicine breakthroughs! As @illumina's partner for nearly a decade and official ICA Implementation Partner, we're proud to support platforms like ICA that power these innovations. Here's to more discoveries ahead! 🚀 #Genomics #PrecisionMedicine

[Illumina @illumina]

In Q3, we brought our mission to life across multiomics, oncology, and data-driven discovery — strengthening our leadership in precision medicine.

1️⃣ Accelerating proteomics at scale
We launched Illumina Protein Prep, expanding next-generation proteomics to researchers worldwide. Measuring 9,500 unique human protein targets, it’s helping uncover new biomarkers across cancer, cardiometabolic, and immune diseases. Early data from a study by Genomics England [tag] showed a 7.5% boost in diagnostic yield for rare disease, underscoring the power of multiomics to transform research insights into impact.

2️⃣ Advancing genomic discovery
Alnylam Pharmaceuticals [tag] joined the Alliance for Genomic Discovery (AGD), expanding one of the world’s most diverse clinical genomic datasets. Leveraging DRAGEN™ and Illumina Connected Analytics, the alliance is accelerating therapeutic discovery across populations and disease areas.

3️⃣ Expanding access to precision oncology
New pharma collaborations will develop KRAS-focused companion diagnostics on TruSight™ Oncology Comprehensive — a key step toward globally distributable, tumor-agnostic testing that connects more patients to targeted therapies.

4️⃣ Leading with purpose
For the second consecutive year, Illumina was named to [tag]TIME’s World’s Most Sustainable Companies list and U.S. News & World Report’s Best Companies to Work For. From 100% renewable electricity to an 80% reduction in packaging, our commitment to sustainability and people remains central to how we innovate.

Together, these achievements highlight our commitment to science, clinical translation, and sustainability — all in service of our mission to unlock the power of the genome to improve human health.

Learn more at https://t.co/b8DazzleFC

[Illumina @illumina]

In Q3, we brought our mission to life across multiomics, oncology, and data-driven discovery — strengthening our leadership in precision medicine.

1️⃣ Accelerating proteomics at scale
We launched Illumina Protein Prep, expanding next-generation proteomics to researchers worldwide. Measuring 9,500 unique human protein targets, it’s helping uncover new biomarkers across cancer, cardiometabolic, and immune diseases. Early data from a study by Genomics England [tag] showed a 7.5% boost in diagnostic yield for rare disease, underscoring the power of multiomics to transform research insights into impact.

2️⃣ Advancing genomic discovery
Alnylam Pharmaceuticals [tag] joined the Alliance for Genomic Discovery (AGD), expanding one of the world’s most diverse clinical genomic datasets. Leveraging DRAGEN™ and Illumina Connected Analytics, the alliance is accelerating therapeutic discovery across populations and disease areas.

3️⃣ Expanding access to precision oncology
New pharma collaborations will develop KRAS-focused companion diagnostics on TruSight™ Oncology Comprehensive — a key step toward globally distributable, tumor-agnostic testing that connects more patients to targeted therapies.

4️⃣ Leading with purpose
For the second consecutive year, Illumina was named to [tag]TIME’s World’s Most Sustainable Companies list and U.S. News & World Report’s Best Companies to Work For. From 100% renewable electricity to an 80% reduction in packaging, our commitment to sustainability and people remains central to how we innovate.

Together, these achievements highlight our commitment to science, clinical translation, and sustainability — all in service of our mission to unlock the power of the genome to improve human health.

Learn more at https://t.co/b8DazzleFC

[United Mitochondrial Disease Foundation @UMDF]

HUGE NEWS! The FDA has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease thymidine kinase 2 deficiency (TK2d). You can find the full prescribing details and announcement here: https://t.co/4XXSZxmD4Q

[Strand Life Sciences @StrandLife]

Great to see our work with the Seqera Platform featured in a new case study, now live on the @Seqera website.

We're focused on helping life sciences organizations solve their biggest data challenges. This story highlights how we partner with clients to deliver the expert Nextflow implementation services they need to accelerate their science.

Read the details here: https://t.co/IMz8r2ca89

#Bioinformatics #Nextflow #Genomics #Implementation #LifeSciences

[Strand Life Sciences @StrandLife]

Amid uncertainty, one trend is unmistakable: 85% of top pharma companies are investing more in #AI, making it an immediate priority—even as budgets tighten.

The new @BioSpace report (link below) is a fascinating pulse-check: “Business as usual” is no longer a winning strategy when speed to market and operational efficiency define who leads and who follows.

From what we see at Strand, this sector-wide urgency matches real-world conversations.

Most forward-thinking teams aren’t just experimenting at the edges—they’re integrating AI into core workflows, sometimes with help from partners who build, automate, and guide alongside internal teams.

The best results often come from blending internal scientific expertise with flexible outside support to optimize pipelines, close skill gaps, and deliver value now, not in next year’s planning cycle.

For organizations wrestling with bandwidth, skills gaps, or the question of “buy vs. build,” a collaborative approach is fast becoming the industry standard. In our work, we’ve seen that transparent partnerships, iterative delivery, and a focus on solving genuine bottlenecks—not chasing hype—pay lasting dividends.

AI is no longer a niche project in this field. It’s the backbone of what’s next.

🔗 Read the full article: https://t.co/XtcgFLwN56

#LifeSciences #Pharma #DigitalTransformation #AIInPharma #Consulting #Strand

[Strand Life Sciences @StrandLife]

As we gear up for our fun-filled event this week, we're excited to announce we have 2 more talks lined up. So make sure to register today for an evening of engaging talks, great food, and networking!
📅 September 10, 2025
📍 Myriad Genetics' SSF facility in the Grand Nexus Building, 233 E Grand Ave. South San Francisco, CA
⏰ 5 - 9PM PST

Hosted by Shane Brubaker, this program features experts from Myriad Genetics, Strand Life Sciences, Roke Biotechnologies, and Castle Biosciences, Inc., presenting real-world applications in bioinformatics.

🎤 Featured Talks:

▫️ Talk 1 (Roke Biotechnologies): Unlocking Advanced Protein Manufacturing Using Systems Engineering
Presenter: Romel Menacho Melgar, CEO of Roke Biotechnologies

▫️ Talk 2 (Strand Life Sciences): Automated Metadata Ingestion and Harmonization in Strand's scRNA-seq Portal and Beyond
Presenter: Badri Padhukasahasram, VP of Data Science, Strand Life Sciences

▫️ Talk 3 (Strand Life Sciences & Myriad Genetics): Master Infrastructure Set Up for Multiple Pipeline Integrations in Minimal Residual Disease (MRD)
Presenters:
Moulika Kirthi, Software Engineer, Strand Life Sciences
Radhakrishna Bettadapura, VP, Research Informatics, Strand Life Sciences
Erik Anderson, Staff Software Engineer, Myriad Genetics
Benjamin Vaisvil, Staff Software Engineer, Myriad Genetics

▫️ Talk 4 (Castle Biosciences, Inc. Biosciences Inc.): Genetic Algorithms For High Dimensional Feature Refinement
Presenter: Kyle Covington, Director of Bioinformatics, Castle Biosciences Inc

The event will be recorded. For a copy, contact Jaya Singh, PhD ([email protected]) or Shane Brubaker ([email protected]).

👉 Register here: https://t.co/mtf5WOfLbz

Parking will be available in the Nexus garage (next to Myriad) until 9:30PM.

hashtag#BayAreaBioinformatics
hashtag#GenomicsData
hashtag#GenomicsWorkflows
hashtag#NGSWorkflows
hashtag#ComputationalGenomics
hashtag#BioinformaticsTools
hashtag#BioinformaticsSolutions
hashtag#BioinformaticsInfrastructure
hashtag#PipelineAutomation

[Strand Life Sciences @StrandLife]

Big news from OpenAI and Oracle on the Stargate project! They're expanding with an additional 4.5 gigawatts of data center capacity in the U.S., pushing the total to over 5 gigawatts, with parts of the Stargate I site in Abilene, Texas, already operational. This is a massive step for AI infrastructure, and it’s got me thinking about what it means for genomics analysis and drug discovery.
At Strand Life Sciences, we’re all about tackling complex bioinformatics challenges, from building NGS pipelines to curating multi-omics data for pharma and diagnostics companies. The Stargate project’s scale—potentially powering over 2 million Nvidia chips—could be a game-changer for our field. With this kind of compute power, we could see faster processing of large-scale genomic datasets, like whole-exome sequencing or single-cell RNA-seq. It could accelerate variant interpretation, cutting rare disease diagnosis times significantly. For drug discovery, this infrastructure could enable more robust AI-driven biomarker studies or protein interaction analyses.
But here’s the flip side—will this massive compute boost be accessible enough for smaller players in genomics and drug discovery, or will it mostly benefit the big dogs? And with the industry already navigating funding uncertainties, as we’ve seen with recent NIH cuts, how will this shape R&D priorities?
I’d love to hear your thoughts. How do you see this kind of AI infrastructure impacting genomics and drug discovery? If you’re grappling with data challenges or looking to leverage AI for your pipelines, let’s connect—I’m happy to chat about how Strand can help. https://t.co/YEPSQcUBH8

[Business Today @business_today]

#BTMagazine | Ramesh Hariharan, CEO of @StrandLife, shares how owning up to failure—rather than shifting blame—helped the Bengaluru-based in silico tech firm bounce back from a funding crisis and emerge stronger.

https://t.co/POp62Aq9qS

[Strand Life Sciences @StrandLife]

https://t.co/I4mH9YkH3L

The Science Circuit

Friday, 20 December 2024

Unlocking Insights: Simplifying Single-Cell Data with Strand’s scRNA Portal
Simplifying single-cell data exploration with Strand’s scRNA portal

In the rapidly advancing world of single-cell RNA sequencing (scRNA-seq), navigating complex datasets can be a major challenge. Strand’s scRNA Portal is designed to transform this challenge into an opportunity by harmonizing publicly available datasets, making disease-specific omics data accessible, actionable, and ready for discovery.